非小细胞肺癌组织HMGB1表达临床意义Meta分析

Expression and clinical significance of HMGB1 in non-small cell lung cancer:A Meta-analysis

目的多项研究表明,高迁移族蛋白B1(hight mobility group box 1,HMGB1)在非小细胞肺癌(non-small cell lung cancer,NSCLC)的发生发展中起到关键作用,本研究旨在通过Meta分析评价NSCLC组织HMGB1的表达与各临床病理参数相关性。方法计算机检索PubMed、中国期刊全文数据库、万方数据库和维普数据库中NSCLC组织HMGB1表达情况与各临床病理参数相关性的文章,搜索时限为2000-01-2016-12,经过两名作者独立评价文献质量后,采用Revman 5.1软件对纳入的研究进行Meta分析。结果共检索到125篇文献,根据纳入标准总计6篇文献符合要求被纳入分析,累计病例536例。Meta分析示,HMGB1蛋白的表达水平与患者的性别无显著相关性(P>0.05),而与患者临床分期、组织分化程度、病理类型及是否有淋巴结转移密切相关,均P<0.05。临床分期较晚(P=0.003)、肿瘤分化程度较低(P<0.05)、有淋巴结转移(P<0.000 01)、病理类型为腺癌(P=0.001)的癌组织HMGB1阳性表达率较高。结论 NSCLC患者癌组织HMGB1的表达情况与患者临床分期、组织分化程度、病理类型及是否有淋巴结转移密切相关,有望成为判定NSCLC侵袭、转移、耐药及预后的重要标记物。但纳入的研究样本量小,质量一般,仍需要更多大样本、多中心和多因素分析的临床研究进一步证实。

OBJECTIVE Previous studies have found that HMGB1 plays an important role in the occurance and development of NSCLC.This paper aimed at investigating the relationship between the expression of High Mobility Group Box-1（HMGB1）and clinical-pathological factors in non-small cell lung cancer（NSCLC）tissues through a meta-analysis.METHODS The databases of PubMed,CNKI,Wanfang and VIP were retrieved for collecting the articles about the relationship between the expression of HMGB1 and clinical-pathological factors of NSCLC tissues from January 2000 to December 2016.After the critical evaluation of two authors on the quality of articles,the extracted data was analyzed by Revmen 5.1software.RESULTS The original study yielded 125 relevant articles.According to the inclusion criteria,a total of 6articles,536 patients,were included.The rate of HMGB1 positive expression in the NSCLC tissues was significantly related with clinical stage,differentiation degree of tissues,adenocarcinoma and lymph node metastasis.Tumor tissues with advanced clinical stage（P=0.003）,poorly differentiation（P〈0.05）,lymph node metstases（P0.000 01）and adenocarcinoma（P=0.001）is of higher HMGB1 positive expression rate.CONCLUSIONS HMGB1 is promising to serve as an indicator to evaluate the progression,metastasis,drug resistance and prognosis of NSCLC patients.Due to the limitations of the relatively low quality and small sample of studies included,more large-sample,multi-center and multi-factor analysis of clinical studies are required.